{{ $DoctorName }} @if (isset(session()->get('doctor')['vCentralCode'])) {{ session()->get('doctor')['vCentralCode'] }} @endif
@if (isset(session()->get('doctor')['vCentralCode']))
Logout
@endif

{{ $ActivityTypeName }}

{{ $ActivityName }}

@csrf
@if (isset(session()->get('doctor')['vCentralCode']))
Back
@else
@endif

Understanding Clinical Usage Pattern of Triple Drug Combination (Brimonidine + Brinzolamide + Timolol) in Primary Open Angle Glaucoma: A cross sectional survey
Doctor's details
@if (isset(session()->get('doctor')['vCentralCode']))
@else
@endif
@if (isset(session()->get('doctor')['vCentralCode']))
@else
@endif

Questionnaire

  1. How many Primary Open Angle Glaucoma patients do you see per month? *

  2. How long have you been prescribing the triple drug combination (Brimonidine + Brinzolamide + Timolol)? *

  3. How often do you prescribe this medication to your patients? *

  4. How often do you prescribe the triple drug combination (Brimonidine + Brinzolamide + Timolol) to be administered to your patients? *

  5. For what duration do you typically prescribe the triple drug combination (Brimonidine + Brinzolamide + Timolol) to your patients? *

  6. What was the most common previous treatment for your patients before starting this combination therapy? (Please describe in detail.)*
  7. In which severity of POAG patient do you prescribe triple drug combination? (Select all that apply) *

  8. What percentage reduction in intraocular pressure (IOP) do you typically observe in your patients using the triple drug combination (Brimonidine + Brinzolamide + Timolol)? *

  9. How effective do you find the triple drug combination in controlling intraocular pressure in your patients? *

  10. How quickly do your patients typically notice an improvement in their symptoms after starting the medication?*

  11. Have you observed any reduction in visual field loss in your patients since starting the medication? (Please describe the extent of reduction and any relevant observations.) *
  12. How would you rate the overall effectiveness of the medication on a scale of 1 to 10? *

  13. What percentage of your patients treated with the triple drug combination (Brimonidine + Brinzolamide + Timolol) report experiencing adverse events? *

  14. How would you rate the tolerability of the medication on a scale of 1 to 10? *

  15. Do your patients have any other medical conditions that might affect their glaucoma treatment?(Please provide details on any such conditions and how they impact the treatment.)*
  16. Have your patients ever considered stopping the medication? (If yes, why?) *

  17. How satisfied are your patients with the triple drug combination therapy overall? *

  18. What is the average duration of follow-up for your patients on the triple drug combination? *

  19. Have you observed any changes in patient adherence to the medication regimen since starting the triple drug combination? *

  20. What factors do you believe contribute to patient adherence to the triple drug combination? (Please elaborate on the key factors) *
  21. How do you rate the cost-effectiveness of the triple drug combination compared to other treatments? *

  22. Have you encountered any challenges in prescribing the triple drug combination? (Please describe the challenges in detail) *
  23. What is the most common reason for discontinuing the triple drug combination in your patients? (Please provide detailed explanation.) *
  24. What additional treatments do you typically consider if the triple drug combination is not effective? (Select all that apply) *

  25. How do you educate your patients about the potential side effects of the triple drug combination? (Please describe the methods you use and provide specific examples or strategies.) *
  26. What improvements would you like to see in the triple drug combination therapy? (Select all that apply) *

  27. How do you assess the long-term effectiveness of the triple drug combination in your patients? (Select all that apply) *

  28. How do you address patient concerns about the side effects of the triple drug combination? (Select all that apply) *

  29. What is your preferred method for staying updated on new treatments and medications for glaucoma? (Select all that apply) *

  30. How do you involve your patients in the decision-making process regarding their glaucoma treatment? (Select all that apply) *

  31. What additional support or resources would help you in managing patients with POAG? (Select all that apply) *

  32. How do you evaluate the impact of the triple drug combination on your patients' quality of life? (Select all that apply) *

  33. As per You what should be the convenient cost per bottle for Triple drug combination of Brimonidine+Brinzolamide+Timolol? *

  34. What are your expectations for future advancements in glaucoma treatment? (Please share your thoughts on potential developments and innovations that could improve patient outcomes.)*
  35. How do you handle patient concerns about the long-term use of the triple drug combination? (Select all that apply) *

  36. How do you ensure patient compliance with the prescribed triple drug combination? (Please describe the strategies and methods you use.) *
  37. How do you manage patients who experience significant side effects from the triple drug combination? (Select all that apply) *

  38. What are the most common misconceptions your patients have about the triple drug combination? (Please describe these misconceptions.) *
  39. How do you educate your patients about the importance of adherence to the triple drug combination therapy? (Select all that apply) *

  40. What is your experience with the availability of the triple drug combination in your region? *